vs
Side-by-side financial comparison of ANI PHARMACEUTICALS INC (ANIP) and loanDepot, Inc. (LDI). Click either name above to swap in a different company.
loanDepot, Inc. is the larger business by last-quarter revenue ($310.3M vs $247.1M, roughly 1.3× ANI PHARMACEUTICALS INC). ANI PHARMACEUTICALS INC runs the higher net margin — 11.1% vs -7.2%, a 18.4% gap on every dollar of revenue. On growth, ANI PHARMACEUTICALS INC posted the faster year-over-year revenue change (29.6% vs 20.5%). ANI PHARMACEUTICALS INC produced more free cash flow last quarter ($29.1M vs $-648.0M). Over the past eight quarters, ANI PHARMACEUTICALS INC's revenue compounded faster (34.1% CAGR vs 18.0%).
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
LoanDepot, sometimes stylized as loanDepot, is an Irvine, California-based nonbank holding company which sells mortgage and non-mortgage lending products.
ANIP vs LDI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $247.1M | $310.3M |
| Net Profit | $27.5M | $-22.5M |
| Gross Margin | — | — |
| Operating Margin | 14.1% | -10.3% |
| Net Margin | 11.1% | -7.2% |
| Revenue YoY | 29.6% | 20.5% |
| Net Profit YoY | 367.5% | 32.4% |
| EPS (diluted) | $1.14 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $247.1M | $310.3M | ||
| Q3 25 | $227.8M | $323.3M | ||
| Q2 25 | $211.4M | $282.5M | ||
| Q1 25 | $197.1M | $273.6M | ||
| Q4 24 | $190.6M | $257.5M | ||
| Q3 24 | $148.3M | $314.6M | ||
| Q2 24 | $138.0M | $265.4M | ||
| Q1 24 | $137.4M | $222.8M |
| Q4 25 | $27.5M | $-22.5M | ||
| Q3 25 | $26.6M | $-4.9M | ||
| Q2 25 | $8.5M | $-13.4M | ||
| Q1 25 | $15.7M | $-21.9M | ||
| Q4 24 | $-10.3M | $-33.2M | ||
| Q3 24 | $-24.2M | $1.4M | ||
| Q2 24 | $-2.3M | $-32.2M | ||
| Q1 24 | $18.2M | $-34.3M |
| Q4 25 | 14.1% | -10.3% | ||
| Q3 25 | 15.9% | -3.2% | ||
| Q2 25 | 6.6% | -11.4% | ||
| Q1 25 | 13.3% | -16.8% | ||
| Q4 24 | -2.3% | -32.7% | ||
| Q3 24 | -13.8% | 1.1% | ||
| Q2 24 | 3.7% | -29.1% | ||
| Q1 24 | 14.8% | -38.2% |
| Q4 25 | 11.1% | -7.2% | ||
| Q3 25 | 11.7% | -1.5% | ||
| Q2 25 | 4.0% | -4.7% | ||
| Q1 25 | 8.0% | -8.0% | ||
| Q4 24 | -5.4% | -12.9% | ||
| Q3 24 | -16.3% | 0.4% | ||
| Q2 24 | -1.7% | -12.1% | ||
| Q1 24 | 13.2% | -15.4% |
| Q4 25 | $1.14 | — | ||
| Q3 25 | $1.13 | — | ||
| Q2 25 | $0.36 | — | ||
| Q1 25 | $0.69 | — | ||
| Q4 24 | $-0.45 | — | ||
| Q3 24 | $-1.27 | $0.01 | ||
| Q2 24 | $-0.14 | $-0.18 | ||
| Q1 24 | $0.82 | $-0.19 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $285.6M | $337.2M |
| Total DebtLower is stronger | — | $2.1B |
| Stockholders' EquityBook value | $540.7M | $386.0M |
| Total Assets | $1.4B | $6.9B |
| Debt / EquityLower = less leverage | — | 5.44× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $285.6M | $337.2M | ||
| Q3 25 | $262.6M | $459.2M | ||
| Q2 25 | $217.8M | $408.6M | ||
| Q1 25 | $149.8M | $371.5M | ||
| Q4 24 | $144.9M | $421.6M | ||
| Q3 24 | $145.0M | $483.0M | ||
| Q2 24 | $240.1M | $533.2M | ||
| Q1 24 | $228.6M | $603.7M |
| Q4 25 | — | $2.1B | ||
| Q3 25 | — | $2.1B | ||
| Q2 25 | — | $2.1B | ||
| Q1 25 | — | $2.0B | ||
| Q4 24 | — | $2.0B | ||
| Q3 24 | — | $2.0B | ||
| Q2 24 | — | $2.0B | ||
| Q1 24 | — | $2.3B |
| Q4 25 | $540.7M | $386.0M | ||
| Q3 25 | $505.8M | $433.3M | ||
| Q2 25 | $436.8M | $439.1M | ||
| Q1 25 | $418.6M | $469.3M | ||
| Q4 24 | $403.7M | $506.6M | ||
| Q3 24 | $405.9M | $592.0M | ||
| Q2 24 | $455.8M | $578.9M | ||
| Q1 24 | $452.0M | $637.3M |
| Q4 25 | $1.4B | $6.9B | ||
| Q3 25 | $1.4B | $6.2B | ||
| Q2 25 | $1.3B | $6.2B | ||
| Q1 25 | $1.3B | $6.4B | ||
| Q4 24 | $1.3B | $6.3B | ||
| Q3 24 | $1.3B | $6.4B | ||
| Q2 24 | $920.8M | $5.9B | ||
| Q1 24 | $914.5M | $6.2B |
| Q4 25 | — | 5.44× | ||
| Q3 25 | — | 4.83× | ||
| Q2 25 | — | 4.70× | ||
| Q1 25 | — | 4.30× | ||
| Q4 24 | — | 4.00× | ||
| Q3 24 | — | 3.31× | ||
| Q2 24 | — | 3.41× | ||
| Q1 24 | — | 3.63× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | $-638.7M |
| Free Cash FlowOCF − Capex | $29.1M | $-648.0M |
| FCF MarginFCF / Revenue | 11.8% | -208.9% |
| Capex IntensityCapex / Revenue | 0.5% | 3.0% |
| Cash ConversionOCF / Net Profit | 1.10× | — |
| TTM Free Cash FlowTrailing 4 quarters | $171.4M | $-734.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $30.4M | $-638.7M | ||
| Q3 25 | $44.1M | $43.4M | ||
| Q2 25 | $75.8M | $67.6M | ||
| Q1 25 | $35.0M | $-179.9M | ||
| Q4 24 | $15.9M | $47.7M | ||
| Q3 24 | $12.5M | $-349.2M | ||
| Q2 24 | $17.4M | $-278.3M | ||
| Q1 24 | $18.3M | $-278.5M |
| Q4 25 | $29.1M | $-648.0M | ||
| Q3 25 | $38.0M | $38.7M | ||
| Q2 25 | $71.8M | $61.4M | ||
| Q1 25 | $32.5M | $-186.7M | ||
| Q4 24 | $13.5M | $40.8M | ||
| Q3 24 | $7.7M | $-356.4M | ||
| Q2 24 | $13.0M | $-285.7M | ||
| Q1 24 | $13.7M | $-283.3M |
| Q4 25 | 11.8% | -208.9% | ||
| Q3 25 | 16.7% | 12.0% | ||
| Q2 25 | 34.0% | 21.7% | ||
| Q1 25 | 16.5% | -68.2% | ||
| Q4 24 | 7.1% | 15.8% | ||
| Q3 24 | 5.2% | -113.3% | ||
| Q2 24 | 9.4% | -107.7% | ||
| Q1 24 | 10.0% | -127.2% |
| Q4 25 | 0.5% | 3.0% | ||
| Q3 25 | 2.7% | 1.5% | ||
| Q2 25 | 1.9% | 2.2% | ||
| Q1 25 | 1.3% | 2.5% | ||
| Q4 24 | 1.3% | 2.7% | ||
| Q3 24 | 3.2% | 2.3% | ||
| Q2 24 | 3.2% | 2.8% | ||
| Q1 24 | 3.3% | 2.1% |
| Q4 25 | 1.10× | — | ||
| Q3 25 | 1.66× | — | ||
| Q2 25 | 8.87× | — | ||
| Q1 25 | 2.23× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -255.05× | ||
| Q2 24 | — | — | ||
| Q1 24 | 1.00× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
LDI
Segment breakdown not available.
